NuvOx Therapeutics

Executive Summary

NuvOx Therapeutics is a clinical-stage biopharmaceutical company based in Tucson, Arizona, pioneering a first-in-class oxygen therapeutic platform. The company's lead candidate, NanO₂, is designed to reverse tissue hypoxia—a critical condition of low oxygen that underlies numerous fatal diseases, including stroke, traumatic brain injury, and certain cancers. By improving oxygen delivery from the lungs to the blood and tissues, NanO₂ has the potential to address large unmet medical needs across multiple indications. The platform leverages a proprietary nano-sized oxygen carrier that can be administered intravenously, offering a unique mechanism that differentiates it from other oxygen therapies.

Upcoming Catalysts (preview)

• Q2 2026Initiation of Phase 2 clinical trial for NanO₂ in ischemic stroke65% success
• H2 2026Announcement of strategic partnership or licensing deal for oncology indications40% success
• Q3 2026Grant award from NIH or other governmental agency to support preclinical development in traumatic brain injury70% success